Insmed to present new clinical, pre-clinical, and real-world data in serious and rare lung diseases at the american thoracic society 2023 international conference

—data from retrospective study evaluating the association between hospitalization burden and delay in diagnosis of nontuberculous mycobacterial (ntm) lung disease among patients with chronic obstructive pulmonary disease (copd) to be shared in oral presentation— —researchers to present subgroup analysis from phase 2 willow study evaluating brensocatib treatment outcomes by disease severity in patients with bronchiectasis— bridgewater, n.j. , march 24, 2023 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that eight presentations across three of its pillars—arikayce ® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (tpip)—will be shared at the american thoracic society (ats) 2023 international conference, taking place may 19-24, 2023, in washington, d.c.
INSM Ratings Summary
INSM Quant Ranking